Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, van Doorn HC, Bosse T, van Poelgeest MIE, van der Burg SH.

J Immunother Cancer. 2019 Sep 3;7(1):236. doi: 10.1186/s40425-019-0712-z.

2.

Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer.

Kortekaas KE, Van de Vijver KK, van Poelgeest MIE, Gilks CB, Smit VTHBM, Arif S, Arora D, Faruqi A, Ganesan R, Griffin NR, Hale R, Hock YE, Horn LC, McCluggage WG, Mukonoweshuro P, Park KJ, Rous B, Tanchel B, Van Rompuy AS, van Schalkwyk G, Vella J, Vergine M, Singh N, Bosse T.

Int J Gynecol Pathol. 2019 Aug 26. doi: 10.1097/PGP.0000000000000631. [Epub ahead of print]

PMID:
31460873
3.

No effect of topical digoxin and furosemide gel for patients with external anogenital warts.

Rijsbergen M, Rijneveld R, Todd M, Pagan L, Feiss G, de Koning MNC, van Alewijk DCJG, Klaassen ES, Burggraaf J, Rissmann R, van Poelgeest MIE.

J Eur Acad Dermatol Venereol. 2019 Aug 20. doi: 10.1111/jdv.15894. [Epub ahead of print] No abstract available.

PMID:
31430405
4.

Mobile e-diary application facilitates the monitoring of patient-reported outcomes and a high treatment adherence for clinical trials in dermatology.

Rijsbergen M, Niemeyer-van der Kolk T, Rijneveld R, Pinckaers JHFM, Meshcheriakov I, Bouwes Bavinck JN, van Doorn MBA, Hogendoorn G, Feiss G, Cohen AF, Burggraaf J, van Poelgeest MIE, Rissmann R.

J Eur Acad Dermatol Venereol. 2019 Aug 16. doi: 10.1111/jdv.15872. [Epub ahead of print]

PMID:
31419338
5.

Stereophotogrammetric three-dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus-induced skin lesions.

Rijsbergen M, Pagan L, Niemeyer-van der Kolk T, Rijneveld R, Hogendoorn G, Lemoine C, Meija Miranda Y, Feiss G, Bouwes Bavink JN, Burggraaf J, van Poelgeest MIE, Rissmann R.

J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1506-1512. doi: 10.1111/jdv.15474. Epub 2019 Mar 12.

6.

Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature.

Boer FL, Ten Eikelder MLG, Kapiteijn EH, Creutzberg CL, Galaal K, van Poelgeest MIE.

Cancer Treat Rev. 2019 Feb;73:91-103. doi: 10.1016/j.ctrv.2018.12.005. Epub 2018 Dec 24. Review.

PMID:
30685613
7.

Vulvar Paget disease: A national retrospective cohort study.

van der Linden M, Oonk MHM, van Doorn HC, Bulten J, van Dorst EBL, Fons G, Lok CAR, van Poelgeest MIE, Slangen BMF, Massuger LFAG, de Hullu JA.

J Am Acad Dermatol. 2019 Oct;81(4):956-962. doi: 10.1016/j.jaad.2018.11.016. Epub 2018 Nov 17.

PMID:
30458205
8.

The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy.

Abdulrahman Z, Kortekaas KE, De Vos Van Steenwijk PJ, Van Der Burg SH, Van Poelgeest MI.

Expert Opin Biol Ther. 2018 Dec;18(12):1223-1233. doi: 10.1080/14712598.2018.1542426. Epub 2018 Nov 2. Review.

PMID:
30373410
9.

The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival.

Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Duurland CL, van Unen V, Höllt T, van der Velden LA, van Egmond SL, Kortekaas KE, de Vos van Steenwijk PJ, van Poelgeest MIE, Welters MJP, van der Burg SH.

Clin Cancer Res. 2019 Jan 1;25(1):240-252. doi: 10.1158/1078-0432.CCR-18-1749. Epub 2018 Sep 17.

PMID:
30224343
10.

Genomic Characterization of Vulvar (Pre)cancers Identifies Distinct Molecular Subtypes with Prognostic Significance.

Nooij LS, Ter Haar NT, Ruano D, Rakislova N, van Wezel T, Smit VTHBM, Trimbos BJBMZ, Ordi J, van Poelgeest MIE, Bosse T.

Clin Cancer Res. 2017 Nov 15;23(22):6781-6789. doi: 10.1158/1078-0432.CCR-17-1302. Epub 2017 Sep 12.

11.

Long-Term Oncological Outcome After Conventional Radical Hysterectomy Versus 2 Nerve-Sparing Modalities for Early Stage Cervical Cancer.

van Gent MDJM, Rademaker M, van der Veer JCB, van Poelgeest MIE, Gaarenstroom KN, Putter H, Trimbos JBMZ, de Kroon CD.

Int J Gynecol Cancer. 2017 Oct;27(8):1729-1736. doi: 10.1097/IGC.0000000000001067.

PMID:
28704329
12.

Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients.

van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG, Cohen AF, Melief CJ, Burggraaf J, van Poelgeest MI, van der Burg SH.

Oncoimmunology. 2016 Dec 23;6(2):e1267095. doi: 10.1080/2162402X.2016.1267095. eCollection 2017.

13.

The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer.

Van Meir H, du Burck IJ, de Kam ML, Welters MJP, van der Burg SH, Trimbos JBMZ, de Kroon CD, van Poelgeest MIE.

Eur J Gynaecol Oncol. 2017;38(1):25-32.

PMID:
29767860
14.

Risk factors and treatment for recurrent vulvar squamous cell carcinoma.

Nooij LS, Brand FA, Gaarenstroom KN, Creutzberg CL, de Hullu JA, van Poelgeest MI.

Crit Rev Oncol Hematol. 2016 Oct;106:1-13. doi: 10.1016/j.critrevonc.2016.07.007. Epub 2016 Jul 25. Review.

15.

Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.

van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, Valentijn AR, Goedemans R, van der Minne CE, Verdegaal EM, Trimbos JB, van der Burg SH, Welters MJ.

Cancer Immunol Immunother. 2016 Dec;65(12):1451-1463. Epub 2016 Sep 12.

16.

Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?

Nooij LS, van der Slot MA, Dekkers OM, Stijnen T, Gaarenstroom KN, Creutzberg CL, Smit VT, Bosse T, van Poelgeest MI.

Eur J Cancer. 2016 Sep;65:139-49. doi: 10.1016/j.ejca.2016.07.006. Epub 2016 Aug 3. Review.

PMID:
27497345
17.

Stathmin is a highly sensitive and specific biomarker for vulvar high-grade squamous intraepithelial lesions.

Nooij LS, Dreef EJ, Smit VT, van Poelgeest MI, Bosse T.

J Clin Pathol. 2016 Dec;69(12):1070-1075. doi: 10.1136/jclinpath-2016-203676. Epub 2016 May 25.

PMID:
27226646
18.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
19.

Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17.

Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, Bosse T, Smit VT, van de Velde CJ, Cohen AF, Low PS, Burggraaf J, Vahrmeijer AL.

Oncotarget. 2016 May 31;7(22):32144-55. doi: 10.18632/oncotarget.8282.

20.

Paget disease of the vulva.

van der Linden M, Meeuwis KA, Bulten J, Bosse T, van Poelgeest MI, de Hullu JA.

Crit Rev Oncol Hematol. 2016 May;101:60-74. doi: 10.1016/j.critrevonc.2016.03.008. Epub 2016 Mar 4. Review.

21.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH.

Clin Cancer Res. 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594. Epub 2016 Jan 26.

22.

Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma.

Nooij LS, Ongkiehong PJ, van Zwet EW, Bosse T, Creutzberg CL, Gaarenstroom KN, van Poelgeest MI.

Gynecol Oncol. 2015 Dec;139(3):458-64. doi: 10.1016/j.ygyno.2015.09.081. Epub 2015 Oct 23.

PMID:
26432039
23.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

24.

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR.

Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27.

PMID:
26216383
25.

Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature.

Trietsch MD, Nooij LS, Gaarenstroom KN, van Poelgeest MI.

Gynecol Oncol. 2015 Jan;136(1):143-57. doi: 10.1016/j.ygyno.2014.11.002. Epub 2014 Nov 14. Review.

PMID:
25448458
26.

Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival.

van Esch EM, van Poelgeest MI, Kouwenberg S, Osse EM, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg SH.

Int J Cancer. 2015 Feb 15;136(4):E95-106. doi: 10.1002/ijc.29174. Epub 2014 Sep 15.

27.

Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia.

van Esch EM, van Poelgeest MI, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg SH.

Int J Cancer. 2015 Feb 15;136(4):E85-94. doi: 10.1002/ijc.29173. Epub 2014 Sep 15.

28.

Nerve-sparing radical abdominal trachelectomy versus nerve-sparing radical hysterectomy in early-stage (FIGO IA2-IB) cervical cancer: a comparative study on feasibility and outcome.

van Gent MD, van den Haak LW, Gaarenstroom KN, Peters AA, van Poelgeest MI, Trimbos JB, de Kroon CD.

Int J Gynecol Cancer. 2014 May;24(4):735-43. doi: 10.1097/IGC.0000000000000114.

PMID:
24651626
29.

Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy.

van Esch EM, Tummers B, Baartmans V, Osse EM, Ter Haar N, Trietsch MD, Hellebrekers BW, Holleboom CA, Nagel HT, Tan LT, Fleuren GJ, van Poelgeest MI, van der Burg SH, Jordanova ES.

Int J Cancer. 2014 Aug 15;135(4):830-42. doi: 10.1002/ijc.28713. Epub 2014 Jan 28.

30.

Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia.

van Esch EM, Dam MC, Osse ME, Putter H, Trimbos BJ, Fleuren G, van der Burg SH, van Poelgeest MI.

Int J Gynecol Cancer. 2013 Oct;23(8):1476-83. doi: 10.1097/IGC.0b013e3182a57fd6.

PMID:
24257562
31.

The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.

van Meir H, Kenter GG, Burggraaf J, Kroep JR, Welters MJ, Melief CJ, van der Burg SH, van Poelgeest MI.

Anticancer Agents Med Chem. 2014 Feb;14(2):190-203. Review.

PMID:
24237223
32.

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.

de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, Löwik MJ, Berends-van der Meer DM, van der Minne CE, Loof NM, Stynenbosch LF, Fathers LM, Valentijn AR, Oostendorp J, Osse EM, Fleuren GJ, Nooij L, Kagie MJ, Hellebrekers BW, Melief CJ, Welters MJ, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2014 Feb;63(2):147-60. Epub 2013 Nov 15.

PMID:
24233343
33.

Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.

de Vos van Steenwijk PJ, Ramwadhdoebe TH, Goedemans R, Doorduijn EM, van Ham JJ, Gorter A, van Hall T, Kuijjer ML, van Poelgeest MI, van der Burg SH, Jordanova ES.

Int J Cancer. 2013 Dec 15;133(12):2884-94. doi: 10.1002/ijc.28309. Epub 2013 Jul 5.

34.

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van der Burg SH.

J Transl Med. 2013 Apr 4;11:88. doi: 10.1186/1479-5876-11-88.

35.

Near-infrared fluorescence sentinel lymph node biopsy in vulvar cancer: a randomised comparison of lymphatic tracers.

Schaafsma BE, Verbeek FP, Peters AA, van der Vorst JR, de Kroon CD, van Poelgeest MI, Trimbos JB, van de Velde CJ, Frangioni JV, Vahrmeijer AL, Gaarenstroom KN.

BJOG. 2013 May;120(6):758-64. doi: 10.1111/1471-0528.12173. Epub 2013 Feb 19.

36.

Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.

van Esch EM, Welters MJ, Jordanova ES, Trimbos JB, van der Burg SH, van Poelgeest MI.

Expert Rev Vaccines. 2012 Jul;11(7):821-40. doi: 10.1586/erv.12.56. Review.

PMID:
22913259
37.

Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer.

Schaafsma BE, van der Vorst JR, Gaarenstroom KN, Peters AA, Verbeek FP, de Kroon CD, Trimbos JB, van Poelgeest MI, Frangioni JV, van de Velde CJ, Vahrmeijer AL.

Gynecol Oncol. 2012 Oct;127(1):126-30. doi: 10.1016/j.ygyno.2012.07.002. Epub 2012 Jul 10.

38.

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.

de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, Welters MJ, van Poelgeest MI, Melief CJ, Kenter GG, van der Burg SH.

Cancer Immunol Immunother. 2012 Sep;61(9):1485-92. doi: 10.1007/s00262-012-1292-7. Epub 2012 Jun 9.

39.

Pelvic actinomycosis-like disease due to Propionibacterium propionicum after hysteroscopic removal of an intrauterine device.

Wunderink HF, Lashley EE, van Poelgeest MI, Gaarenstroom KN, Claas EC, Kuijper EJ.

J Clin Microbiol. 2011 Jan;49(1):466-8. doi: 10.1128/JCM.01772-10. Epub 2010 Nov 10.

40.

Nerve sparing in radical surgery for early-stage cervical cancer: yes we should!

de Kroon CD, Gaarenstroom KN, van Poelgeest MI, Peters AA, Trimbos JB.

Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S39-41. doi: 10.1111/IGC.0b013e3181f6381f. Review.

PMID:
20975361
41.

The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors.

Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH.

Int J Cancer. 2011 Jan 15;128(2):379-89. doi: 10.1002/ijc.25361. Epub 2010 Apr 5.

42.

Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia.

van den Hende M, van Poelgeest MI, van der Hulst JM, de Jong J, Drijfhout JW, Fleuren GJ, Valentijn AR, Wafelman AR, Slappendel GM, Melief CJ, Offringa R, van der Burg SH, Kenter GG.

Int J Cancer. 2008 Jul 1;123(1):146-52. doi: 10.1002/ijc.23502.

43.

Preoperative predictors of postsurgical adhesion formation and the Prevention of Adhesions with Plasminogen Activator (PAPA-study): results of a clinical pilot study.

Hellebrekers BW, Trimbos-Kemper TC, Boesten L, Jansen FW, Kolkman W, Trimbos JB, Press RR, van Poelgeest MI, Emeis SJ, Kooistra T.

Fertil Steril. 2009 Apr;91(4):1204-14. doi: 10.1016/j.fertnstert.2008.01.052. Epub 2008 Mar 18.

PMID:
18353314
44.

Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.

de Boer MA, Jordanova ES, van Poelgeest MI, van den Akker BE, van der Burg SH, Kenter GG, Fleuren GJ.

Int J Cancer. 2007 Dec 15;121(12):2711-5.

45.

High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer.

Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH.

Cancer Res. 2007 Jan 1;67(1):354-61.

46.

Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.

van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH.

Int J Cancer. 2006 Feb 1;118(3):675-83.

47.

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.

van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH.

Clin Cancer Res. 2005 Jul 15;11(14):5273-80.

48.

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.

de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH.

Cancer Res. 2004 Aug 1;64(15):5449-55.

49.

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.

Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.

Clin Cancer Res. 2004 May 1;10(9):2954-61.

50.

The influence of ergotamine abuse on psychological and cognitive functioning.

Roon KI, Bakker D, van Poelgeest MI, van Buchem MA, Ferrari MD, Middelkoop HA.

Cephalalgia. 2000 Jun;20(5):462-9.

PMID:
11037742

Supplemental Content

Loading ...
Support Center